N.A. Izbagambetov ¹, D.R. Kaidarova ², R.O. Bolatbekova ¹, A.S. Shinbolatova ², T.E. Valieva ¹, A.E. Aidarov ¹, G.B. Bagatova ¹, A.I. Sarmenova ¹, D.B. Zhaksylykova ¹, A.S. Akkasova ¹, A.A. Yestaeva ¹, A.R. Satanova ²

1. «Almaty Oncological Center» MSE on REM, Almaty, the Republic of Kazakhstan;
2. «Kazakh Institute of Oncology and Radiology» JSC, Almaty, the Republic of Kazakhstan

DOI: https://www.doi.org/10.52532/2521-6414-2023-2-68-9-14

UDC:618.146-006.04-616.036.22-8

Year: 2023 issure: 68 number: 2 pages: 9-14

Download PDF:

ABSTRACT

Relevance: In Kazakhstan, the standardized incidence rate of cervical cancer for 2022 was 19 per 100,000 women, and the mortality rate was 5.9 per 100,000 female population. The overall survival of cervical cancer in the Republic of Kazakhstan for 2022 was 59.6% (95% CI: 50.7-54.2). Since 2008, in Kazakhstan, there has been a National Screening Program for cervical cancer for women from 30 to 70 years old with an interval of 4 years. Almaty is the largest city in Kazakhstan, with a high incidence and mortality from all types of cancer.
The study aimed to analyze the cervical cancer incidence and mortality in Almaty in 2005-2022.
Methods: Epidemiological analysis of cervical cancer incidence in Almaty for 2005-2022 was provided with analyzing reporting forms of documentation. Statistical processing was carried out using the SPSS v. 23.0 software.
Results: Over the past 18 years (2005 to 2022), there has been an increase in the incidence rate from 16 to 18.3 per 100,000 female population and a consistently high mortality rate, which was 6.6 per 100,000 female population in 2022. In 2005, 108 women with cervical cancer were
identified, of which 70% were patients with the first and second stages. In 2022, 198 cases of cervical cancer were registered, where the first stage
accounts for 56.5%. In recent years, there has been an increase in the frequency of registration of new cases of cervical cancer starting from 30-34
years old, with a noticeable increase up to 40-44 years old.
Conclusion: The results of this epidemiological study of cervical cancer incidence and mortality in Almaty indicate the need to improve and intensify screening among women of reproductive age, and introduce a vaccination and screening program using HPV testing.
Keywords: cervical cancer, incidence, mortality, Almaty.

List of sources used:

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram .I, Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries // CA Cancer J. Clin. – 2021. – №71(3). – P. 209-249. https://doi.org/10.3322/caac.21660
2. Кайдарова Д.Р., Шатковская О.В., Онгарбаев Б.Т., Сейсенбаева Г.Т. Показатели онкологической службы Республики Казахстан за 2021 год. / под ред. Д.Р. Кайдаровой. – Алматы, 2022. – 388 с. [Kaidarova D.R., Shatkovskaya O.V., Ongarbaev B.T., Sejsenbaeva G.T. Pokazateli onkologicheskoj sluzhby Respubliki Kazaxstan za 2021 god. / pod red. D.R. Kaidarovoy. – Almaty, 2022. – 388 s. (in Russ.)] https://doi.org/10.52532/1-11-2021-1-384
3. Kaidarova D.R., Kairbayev M.R., Bolatbekova R.O. Morbidity and mortality from cervical cancer from 2010 to 2014 after introduction of the national screening program // Вестник КазНМУ. – 2017. – Т. 1. – С. 174-174 [Vestnik KazNMU. – 2017. – T. 1. – S. 174-174(in Russ.)] https://kaznmu.kz/press/wp-content/uploads/2018/02/MORBIDITY-AND-MORTALITY-FROM-CERVICAL-CANCER-FROM-2010-TO-2014-AFTER-INTRODUCTION-NATIONAL-SCREENING-PROGRAMM.pdf
4. Кайдарова Д.Р., Кайрбаев М.Р., Болатбекова Р.О. Эпидемиология рака шейки матки в Республике Казахстан за 10 лет (2007-2016 гг). // Вопросы Онкологии. – 2017. – №4. – С. 572-579 [Kaidarova D.R., Kairbaev M.R., Bolatbekova R.O. E’pidemiologiya raka shejki matki v Respublike Kazaxstan za 10 let (2007-2016 gg). // Voprosy Onkologii. – 2017. – №4. – S. 572-579 (in Russ.)]. https://doi.org/10.37469/0507-3758-2017-63-4-572-579
5. Нургазиев К.Ш., Жылкайдарова А.Ж., Кайрбаев М.Р., Болатбекова Р.О. Оценка показателей заболеваемости и смертности от рака шейки матки в Республике Казахстан за 2004- 2014 годы // Онкология и радиология Казахстана. – 2016. – № 1 (39). – С. 3-9 [Nurgaziev K.Sh., Zhylkajdarova A.Zh., Kajrbaev M.R., Bolatbekova R.O. Ocenka pokazatelej zabolevaemosti i smertnosti ot raka shejki matki v Respublike Kazaxstan za 2004- 2014 gody // Onkologiya i radiologiya Kazaxstana. – 2016. – № 1 (39). – S. 3-9 (in Russ.)]. http://oncojournal.kz/2016-god-vypusk-39-nomer-1/otsenka-pokazatelej-zabolevaemosti-i
6. Rogovskaya S.I., Shabalova I.P., Mikheeva I.V, Minkina G.N., Podzolkova N.M., Shipulina O.Y., Poljak M. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia // Vaccine. – 2013. – №31(7). – Р. 46-58. https://doi.org/0.1016/j.vaccine.2013.06.043
7. Bolatbekova R., Kaidarova D., Zhylkaidarova A., Sadykova T., Kukubassov Y., Satanova A., Aidarov A. Cervical cancer screening: Twelve years experience of the Kazakhstan National Screening program // J. Clin. Oncol. – 2021. – № 39 (15). – P. e17520-e17520. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e17520
8. Bolatbekova R., Kaidarova D., Dushimova Z., Shatkovskaya O., Zhylkaydarova A., Kukubassov Y., Sadykova T., Satanova A., Bertleuov O., Kaldybekov D. Prevalence of HPV and cytological abnormalities in young women in Almaty, Kazakhstan // J. Clin. Oncol. – 2022. – Vol. №40 (16-suppl). – P. e22503-e22503. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e22503
9. Болатбекова Р.О., Жылкайдарова А.Ж., Кайрбаев М.Р. Мировой опыт скрининга рака шейки матки // Онкология и радиология Казахстана. – 2015. – № 2 (36). – С. 27-29 [Bolatbekova R.O., Zhylkajdarova A.Zh., Kajrbaev M.R. Mirovoj opyt skrininga raka shejki matki // Onkologiya i radiologiya Kazaxstana. – 2015. – № 2 (36). – S. 27-29 (in Russ.)]. http://oncojournal.kz/mirovoj-opyt-skrininga-raka-shejki-mat
10. Кучеренко В.З. Применение методов статистического анализа: учебное пособие . – М., 2004. – 188 с. [Kucherenko V.Z. Primenenie metodov statisticheskogo analiza: uchebnoe posobie. – M., 2004. – 188 s. (in Russ.)]. https://www.studmed.ru/kucherenko-vz-primenenie-metodov-statisticheskogo-analiza-dlya-izucheniya-obschestvennogo-zdorovya-i-zdravoohraneniya_a4125fd9d22.html
11. Ahmad O.B., Boschi-Pinto C., Lopez A.D., Murray C.J.L., Lozano R., Inoue M. Age standardization of rates: a new WHO standard // GPE Discussion Paper Series. – 2001. – No.31. https://cdn.who.int/media/docs/default-source/gho-documents/global-health-estimates/gpe_discussion_paper_series_paper31_2001_age_standardization_rates.pdf
12. Smith M.A., Canfell K. Testing previous model predictions against new data on human papillomavirus vaccination program outcomes // BMC Res. Notes. – 2014. – Vol. 7. – Р. 109-112. https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-7-109
13. Crawford L.V. A study of human papilloma virus DNA // J. Mol. Biol. – 1965. – Vol. 13. – P. 362-372. https://www.sciencedirect.com/science/article/abs/pii/S0022283665801036
14. Stanley M. Pathology and epidemiology of HPV infection in females. // Gynecol. Oncol. – 2010. – Vol. 117(2). – P. 5-10. https://doi.org/10.1016/j.ygyno.2010.01.024
15. Palefsky J.M., Holly E.A. Molecular virology and epidemiology of human papillomavirus and cervical cancer // Cancer Epidemiol. Biomarkers Prev. – 1995. – Vol. 4. – P. 415-428. https://pubmed.ncbi.nlm.nih.gov/7655339/
16. Arbyn M., Rebolj M., De Kok I.M., Fender M., Becker N., O‘Reilly M., Andrae B. The challenges of organising cervical screening programmes in the 15 old member states of the European Union // Eur. J. Cancer. – 2009. – Vol. 45. – Р. 2671-2678. https://doi.org/10.1016/j.ejca.2009.07.016
17. Sankaranarayanan R., Budukh A., Rajkumar R. Effective screening programs for cervical cancer in low- and middle- income developing countries // Bull. World Health Organization. – 2001. – Vol. 79. – Р. 954-962. https://pubmed.ncbi.nlm.nih.gov/11693978/